BioCentury | Mar 28, 2020
Management Tracks
Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
...a CD37-targeted radionuclide therapy to treat lymphoma (see “Radiotherapy Blasts Forward” ). Bone healing company Bioventus Inc....
...Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus Inc....
...Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus Inc....